BASG公布Advanz Pharma召回Mynzepli 40 mg/ml预充式注射器注射液批次2325718

Mynzepli 40 mg/ml - Injektionslösung in einer Fertigspritze

AI 导读

奥地利BASG公布，上市许可持有人Advanz Pharma于2026年10月29日通知客户召回Mynzepli 40 mg/ml预充式注射器注射液批次2325718，原因是预充式注射器指托（finger flange）缺陷。该召回分类为2级，召回深度为药房，涉事批次有效期至2027年5月31日。产品许可编号为EU/1/25/1964/002，BASG参考号为INS-640.001-5907。

推荐理由

材料列出被召回批号、有效期及召回深度仅至药房层级，便于核对在库产品是否涉及该批次。

正文 · 原文

Recall | Medicines | 29/10/2026

The marketing authorisation holder informed its customers on October 29, 2026 that the mentioned batch is being recalled due to defective finger flanges on the pre-filled syringes.

Name of the medicinal product	Mynzepli 40 mg/ml - Injektionslösung in einer Fertigspritze
Marketing authorisation number(s)	EU/1/25/1964/002
CIP code	6060902
Marketing authorisation holder	Advanz Pharma Limited
Batch number(s)	2325718
Expiry date	05/31/2027
Classification of the recall	2
Depth of recall	Pharmacies
BASG reference number	INS-640.001-5907